Impact of COVID19 pandemic on the incidence of health-care associated Clostridioides difficile infection.
Nicolás Merchante, Pablo Chico, Esther Márquez-Saavedra...
https://pubmed.ncbi.nlm.nih.gov/35500744/Actively Recruiting
Led by Hospital Universitario de Valme · Updated on 2026-09-17
750
Participants Needed
15
Research Sites
N/A
Total Duration
Researchers are investigating whether certain host factors, including the variety and makeup of intestinal microbiota and genetic markers, are linked to a higher chance of recurrence of Clostridioides difficile infection CDI. The study aims to create a predictive tool that uses epidemiological, clinical, genetic, and microbiologic data to identify patients at greater risk of CDI coming back, within an optimized CDI management setting. This is a multicenter, prospective observational study involving adults diagnosed with CDI according to IDSA criteria. Participants will be part of a stewardship program designed to improve CDI management and enable early detection of CDI recurrence. Blood samples will be collected for genetic testing, and stool samples will be analyzed to study the intestinal microbiome. The study will monitor patients diagnosed with CDI over time without introducing experimental treatments. Throughout the study, researchers will assess the occurrence of CDI recurrence within the first 8 weeks after therapy ends and reinfection between 8 and 24 weeks post-therapy. They will also track hospital readmissions due to CDI during the 24 weeks following treatment completion. Data will be analyzed to identify predictors of recurrence, and the predictive tools accuracy will be evaluated. Participants may expect periodic monitoring as part of the study lasting until December 2029.
CONDITIONS
Natural History of Clostridioides Difficile Infection
N
Nicolás Merchante, MD; PhD
M
Miguel Rodríguez Fernández
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hospital Universitario de Valme
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 weeks after treatment
Participants provide blood and stool samples for genetic and microbiome studies and are monitored for signs of CDI recurrence or reinfection.
Periodic visits as needed for sample collection and health assessments
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Nicolás Merchante, Pablo Chico, Esther Márquez-Saavedra...
https://pubmed.ncbi.nlm.nih.gov/35500744/Nicolás Merchante, Rocío Herrero, María Dolores Valverde-Fredet...
https://pubmed.ncbi.nlm.nih.gov/36968953/Miguel Rodríguez-Fernández, Rocio Herrero, Pilar González-De-La-Aleja...
https://pubmed.ncbi.nlm.nih.gov/41201562/María-Paz Ventero, María-Dolores Valverde-Fredet, Esperanza Merino...
https://pubmed.ncbi.nlm.nih.gov/41750443/Hospital Universitario de Valme
Lead Sponsor